NASDAQ:FIXX Homology Medicines Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Homology Medicines Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.04 -0.21 (-1.87 %) (As of 09/23/2020 02:50 PM ET) Add Compare Share Today's Range$10.95Now: $11.04▼$11.4550-Day Range$9.94MA: $11.06▼$14.2552-Week Range$9.19Now: $11.04▼$22.50Volume18,241 shsAverage Volume412,048 shsMarket Capitalization$499.21 millionP/E RatioN/ADividend YieldN/ABeta-0.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle, and eye in gene editing and gene therapy modalities. Its lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingHomology Medicines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.43, Homology Medicines has a forecasted upside of 173.6% from its current price of $11.12.Amount of Analyst CoverageHomology Medicines has only been the subject of 4 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesHomology Medicines has received 95 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHomology Medicines has received 89 “underperform” votes. (Add your “underperform” vote.)Community SentimentHomology Medicines has received 51.63% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Homology Medicines and other stocks. Vote “Outperform” if you believe FIXX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FIXX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHomology Medicines does not currently pay a dividend.Dividend GrowthHomology Medicines does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Homology Medicines insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 28.00% of the stock of Homology Medicines is held by insiders.Percentage Held by Institutions83.28% of the stock of Homology Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Homology Medicines are expected to grow in the coming year, from ($3.16) to ($2.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Homology Medicines is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Homology Medicines is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHomology Medicines has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.55 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FIXX Previous Symbol CUSIPN/A CIK1661998 Webwww.homologymedicines.com Phone781-301-7277Debt Debt-to-Equity RatioN/A Current Ratio10.72 Quick Ratio10.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.67 million Price / Sales298.93 Cash FlowN/A Price / Cash FlowN/A Book Value$5.73 per share Price / Book1.93Profitability EPS (Most Recent Fiscal Year)($2.47) Net Income$-103,920,000.00 Net Margins-5,764.94% Return on Equity-53.10% Return on Assets-42.39%Miscellaneous Employees124 Outstanding Shares45,218,000Market Cap$499.21 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $11.04 -0.21 (-1.87 %) (As of 09/23/2020 02:50 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive FIXX News and Ratings via Email Sign-up to receive the latest news and ratings for FIXX and its competitors with MarketBeat's FREE daily newsletter. Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions How has Homology Medicines' stock price been impacted by COVID-19 (Coronavirus)? Homology Medicines' stock was trading at $17.91 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, FIXX stock has decreased by 38.4% and is now trading at $11.04. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Homology Medicines? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Homology Medicines. When is Homology Medicines' next earnings date? Homology Medicines is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Homology Medicines. How were Homology Medicines' earnings last quarter? Homology Medicines Inc (NASDAQ:FIXX) posted its earnings results on Monday, August, 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.74) by $0.04. The firm earned $0.57 million during the quarter, compared to analysts' expectations of $0.47 million. Homology Medicines had a negative net margin of 5,764.94% and a negative return on equity of 53.10%. View Homology Medicines' earnings history. What price target have analysts set for FIXX? 7 equities research analysts have issued 1-year target prices for Homology Medicines' shares. Their forecasts range from $27.00 to $34.00. On average, they anticipate Homology Medicines' share price to reach $30.43 in the next twelve months. This suggests a possible upside of 175.6% from the stock's current price. View analysts' price targets for Homology Medicines. Who are some of Homology Medicines' key competitors? Some companies that are related to Homology Medicines include Harmony Biosciences (HRMY), Seres Therapeutics (MCRB), Zymeworks (ZYME), CytoDyn (CYDY), Madrigal Pharmaceuticals (MDGL), Intra-Cellular Therapies (ITCI), Aurinia Pharmaceuticals (AUPH), Akcea Therapeutics (AKCA), Revance Therapeutics (RVNC), Uniqure (QURE), CryoPort (CYRX), Prestige Consumer Healthcare (PBH), Eidos Therapeutics (EIDX), Kura Oncology (KURA) and Ironwood Pharmaceuticals (IRWD). View all competitors. What other stocks do shareholders of Homology Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Canopy Growth (CGC), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD) and Gilead Sciences (GILD). Who are Homology Medicines' key executives? Homology Medicines' management team includes the following people: Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 56)Mr. Timothy P. Kelly, Chief Technical Operations Officer (Age 50)Dr. Albert Seymour Ph.D., Chief Scientific Officer (Age 51)Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory BoardMr. W. Bradford Smith, CFO, Treasurer & Sec. (Age 63) When did Homology Medicines IPO? (FIXX) raised $100 million in an initial public offering (IPO) on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI served as the underwriters for the IPO and BTIG was co-manager. What is Homology Medicines' stock symbol? Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX." Who are Homology Medicines' major shareholders? Homology Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include RTW Investments LP (9.62%), FMR LLC (4.94%), Bellevue Group AG (3.84%), Vanguard Group Inc. (3.25%), Cormorant Asset Management LP (1.22%) and Goldman Sachs Group Inc. (0.88%). Company insiders that own Homology Medicines stock include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Siyamak Rasty, Timothy P Kelly, Ventures Iv LP 5Am and W Bradford Smith. View institutional ownership trends for Homology Medicines. Which institutional investors are selling Homology Medicines stock? FIXX stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, and RTW Investments LP. Company insiders that have sold Homology Medicines company stock in the last year include Albert Seymour, Arthur Tzianabos, James E Flynn, Timothy P Kelly, and W Bradford Smith. View insider buying and selling activity for Homology Medicines. Which institutional investors are buying Homology Medicines stock? FIXX stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Vanguard Group Inc., Jacobs Levy Equity Management Inc., Point72 Asset Management L.P., Bellevue Group AG, Sofinnova Investments Inc., Verition Fund Management LLC, and Bessemer Group Inc.. View insider buying and selling activity for Homology Medicines. How do I buy shares of Homology Medicines? Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Homology Medicines' stock price today? One share of FIXX stock can currently be purchased for approximately $11.04. How big of a company is Homology Medicines? Homology Medicines has a market capitalization of $499.21 million and generates $1.67 million in revenue each year. The company earns $-103,920,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Homology Medicines employs 124 workers across the globe. What is Homology Medicines' official website? The official website for Homology Medicines is www.homologymedicines.com. How can I contact Homology Medicines? Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277. This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
